Out-patient management of chronic heart failure

Bibliography

• HUNT SA, BAKER DW, CHIN MH et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. CardioL (2001) 38:2101–2113.
   Google Scholar
• REMME WJ, SWEDBERG K: for the diagnosis and treatment of chronic heart failure. Eur. Heart J. (2001) 22:1527–1560.
   PubMed Web of Science ®Google Scholar
• KANNEL WB: Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur. Heart J. (1987) 8(Suppl. F):23–26.
   Google Scholar
• O'CONNELL JB, BRISTOW MR: Economic impact of heart failure in the United States: time for a different approach. J. Heart Lung Transplant. (1994) 13:S107–S112.
   Web of Science ®Google Scholar
• STAFFORD RS, RADLEY DC: The underutilization of cardiac medications of proven benefit, 1990 to 2002.. Am. Coll. CardioL (2003) 41:56–61.
   PubMed Web of Science ®Google Scholar
• FRANCIS GS, TANG WH: Pathophysiology of congestive heart failure. Rev. Cardiovasc. Med. (2003) 4\(Suppl. 2):514–520.
   Google Scholar
• GHEORGHIADE M, BONOW RO: Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation (1998) 97:282–289.
   PubMed Web of Science ®Google Scholar
• JESSUP M, BROZENA S: Heart failure. N EngL J. Med. (2003) 348:2007-2018. Excellent review describing the pathophysiological changes taking place in heart failure and its management according to stages of the disease.
   Google Scholar
• KJEKSHUS J, PEDERSEN TR, AG, FAERGEMAN O, PYORALA K: The effects of simvastatin on the incidence of heart failure in patients coronary heart disease. J. Card. Fail. (1997) 3:249–254.
   PubMedGoogle Scholar
• KOSTIS JB, DAVIS BR, CUTLER J et al.: Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA (1997) 278:212–216.
   PubMed Web of Science ®Google Scholar
• HE J, OGDEN LG, BAZZANO LA et al.: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study.. Intern. Med. (2001) 161:996–1002.
   Web of Science ®Google Scholar
• SHINDLER DM, KOSTIS JB, YUSUF S et al.: Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am. J. CardioL (1996) 77:1017–1020.
   PubMed Web of Science ®Google Scholar
• ARNOLD JM, YUSUF S, YOUNG Jet al.:Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation (2003) 107:1284–1290.
   Google Scholar
• GUERCI AD, GERSTENBLITH G, BRINKER JA et al.: A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N EngL J. Med. (1987) 317:1613–1618.
   PubMed Web of Science ®Google Scholar
• HERLITZ J, WAAGSTEIN F, LINDQVIST J, SWEDBERG K, HJALMARSON A: Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial). Am. J. CardioL (1997) 80:40J–44J.
   Google Scholar
• NO AUTHORS LISTED]: Angiotensin converting enzyme inhibition in stable coronary artery disease. The PEACE trial investigators. N Engl. J. Med. (2004) 351:2058–2068.
   PubMed Web of Science ®Google Scholar
• COHN JN, ARCHIBALD DG, ZIESCHE S et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N EngL J. Med. (1986) 314:1547–1552.
   Google Scholar
• TAYLOR AL, ZIESCHE S, YANCY C et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N EngL J. Med. (2004) 351:2049–2057.
   PubMed Web of Science ®Google Scholar
• IGNARRO LJ, NAPOLI C, J: Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ. Res. (2002) 90:21–28.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED]: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N EngL J. Med. (1987) 316:1429–1435.
   Google Scholar
• NO AUTHORS LISTED]: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N EngL J. Med. (1991) 325:293–302.
   PubMed Web of Science ®Google Scholar
• COHN JN, JOHNSON G, ZIESCHE S et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl. J. Med. (1991) 325:303–310.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED]: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N EngL J. Med. (1992) 327:685–691.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, BRAUNWALD E, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N EngL J. Med. (1992) 327:669–677.
   Google Scholar
• KOBER L, TORP-PEDERSEN C, CARLSEN JE et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N EngL J. Med. (1995) 333:1670–1676.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED]: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. (1993) 342:821–828.
   Google Scholar
• FLATHER MD, YUSUF S, KOBER L et al.: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet (2000) 355:1575–1581.
   PubMed Web of Science ®Google Scholar
• YUSUF S, SLEIGHT P, POGUE J et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. J. Med. (2000) 342:145–153.
   PubMed Web of Science ®Google Scholar
• HAVRANEK EP, ABRAMS F, E, PARKER K: Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch. Intern. Med. (1998) 158:2024–2028.
   PubMedGoogle Scholar
• SHEKELLE PG, RICH MW, SC et al.: Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.. Am. Coll. CardioL (2003) 41:1529–1538.
   PubMed Web of Science ®Google Scholar
• EXNER DV, DRIES DL, MJ, COHN JN: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N EngL J. Med. (2001) 344:1351–1357.
   PubMed Web of Science ®Google Scholar
• AL-KHADRA AS, SALEM DN, WM et al.: Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J. Am. Coll. Cardiol. (1998) 31:419–425.
   PubMed Web of Science ®Google Scholar
• CICOIRA M, ZANOLLA L, FRANCESCHINI Let al.: Relation of aldosterone 'escape' despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. CardioL (2002) 89:403–407.
   Google Scholar
• NO AUTHORS LISTED]: Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators.. Heart J. (1998) 19:481–489.
   Google Scholar
• NANAS JN, ALEXOPOULOS GP, ANASTASIOU-NANA MI et aL: Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group.. Am. Coll. CardioL (2000) 36:2090–2095.
   PubMed Web of Science ®Google Scholar
• PACKER M, POOLE-WILSON PA, ARMSTRONG PW et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 100:2312–2318.
   PubMed Web of Science ®Google Scholar
• SCHOOLWERTH AC, SICA DA, BALLERMANN BJ, WILCOX CS: Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation (2001) 104:1985–1991.
   PubMed Web of Science ®Google Scholar
• •Description of the effects of ACEIs on renal function and recommendations regarding their administration in patients with pre-existent renal failure or fluctuating renal function.
   Google Scholar
• SHLIPAK MG: Pharmacotherapy for heart in patients with renal insufficiency. Ann. Intern. Med. (2003) 138:917–924.
   PubMed Web of Science ®Google Scholar
• •Very useful recommendations regarding the optimal pharmacological treatment of patients with heart failure and renal insufficiency.
   Google Scholar
• CICARDI M, ZINGALE L, L, AGOSTONI A: Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch. Intern. Med. (2004) 164:910–913.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR, GINSBURG R, MINOBE Wet al.: Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N EngL J. Med. (1982) 307:205–211.
   Google Scholar
• DOUGHTY RN, RODGERS A, SHARPE N, MACMAHON S: Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic of randomized controlled trials. Eur. Heart J. (1997) 18:560–565.
   PubMed Web of Science ®Google Scholar
• HEIDENREICH PA, LEE TT, BM: Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J. Am. Coll. CardioL (1997) 30:27–34.
   PubMed Web of Science ®Google Scholar
• LECHAT P, PACKER M, CHALON S et al.: Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. (1998) 98:1184–1191.
   Google Scholar
• WAAGSTEIN F, BRISTOW MR, SWEDBERG K et al.: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 342:1441–1446.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED]: Effect of metoprolol CRAL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353:2001–2007.
   PubMed Web of Science ®Google Scholar
• PACKER M, BRISTOW MR, COHN JN et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N EngL J. Med. (1996) 334:1349–1355.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED]: A randomizedtrial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation (1994) 90:1765–1773.
   Google Scholar
• NO AUTHORS LISTED]: Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. (1999) 353:9–13.
   Google Scholar
• BROPHY JM, JOSEPH L, ROULEAU JL: Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann. Intern. Med. (2001) 134:550–560.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED]: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. Engl. J. Med. (2001) 344:1659–1667.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN S, FAGERBERG B, HJALMARSON A et al.: Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J. Am. Coll. CardioL (2001) 38:932–938.
   PubMed Web of Science ®Google Scholar
• PACKER M, COATS AJ, FOWLER MB et al.: Effect of carvedilol on survival in chronic heart failure. N EngL J. Med. (2001) 344:1651–1658.
   PubMed Web of Science ®Google Scholar
• DARGIE HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (2001) 357:1385–1390.
   PubMed Web of Science ®Google Scholar
• METRA M, GIUBBINI R, NODARI S et al.: Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation (2000) 102:546–551.
   PubMed Web of Science ®Google Scholar
• POOLE-WILSON PA, SWEDBERG K, CLELAND JG et aL: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 362:7–13.
   PubMed Web of Science ®Google Scholar
• ROULEAU JL, ROECKER EB, TENDERA M et aL: Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J. Am. Coll. CardioL (2004) 43:1423–1429.
   PubMed Web of Science ®Google Scholar
• YANCY CW, FOWLER MB, COLUCCI WS et aL: Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N EngL J. Med. (2001) 344:1358–1365.
   PubMed Web of Science ®Google Scholar
• REMME WJ, RIEGGER G, P et aL: The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc. Drugs Ther. (2004) 18:57–66.
   Google Scholar
• SLIWA K, NORTON GR, KONE Net al.: Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure./ Am. Coll. CardioL (2004) 44:1825–1830.
   Google Scholar
• WIKSTRAND J, HJALMARSON A, WAAGSTEIN F et aL: Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J. Am. Coll. CardioL (2002) 40:491–498.
   PubMed Web of Science ®Google Scholar
• GATTIS WA, O'CONNOR CM, GALLUP DS, HASSELBLAD V, GHEORGHIADE M: Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J. Am. Coll. CardioL (2004) 43:1534–1541.
   PubMed Web of Science ®Google Scholar
• WILKOFF BL, COOK JR, EPSTEIN AE et al.: Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. /AMA (2002) 288:3115–3123.
   PubMed Web of Science ®Google Scholar
• MACDONALD PS, KEOGH AM, ABOYOUN CL et aL: Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J. Am. Coll. CardioL (1999) 33:924–931.
   PubMed Web of Science ®Google Scholar
• METRA M, NODARI S, D'ALOIA A et al.: Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.. Am. Coll. CardioL (2002) 40:1248–1258.
   Google Scholar
• JONG P, DEMERS C, MCKELVIE RS, LIU PP: Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J. Am. Coll. CardioL (2002) 39:463–470.
   PubMed Web of Science ®Google Scholar
• MAGGIONI AP, ANAND I, S et al.: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.. Am. Coll. CardioL (2002) 40:1414–1421.
   PubMed Web of Science ®Google Scholar
• GRANGER CB, MCMURRAY JJ, YUSUF S et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 362:772–776.
   PubMed Web of Science ®Google Scholar
• PITT B, SEGAL R, MARTINEZ FA et aL:Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349:747–752.
   PubMed Web of Science ®Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355:1582–1587.
   PubMed Web of Science ®Google Scholar
• DICKSTEIN K, KJEKSHUS J: Effects oflosartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet (2002) 360:752–760.
   Google Scholar
• COHN JN, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. EngL J. Med. (2001) 345:1667–1675.
   PubMed Web of Science ®Google Scholar
• MCMURRAY JJ, OSTERGREN J, SWEDBERG K et aL: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:767–771.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, MCMURRAY JJ, VELAZQUEZ EJ et aL: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl. J. Med. (2003) 349:1893–1906.
   PubMed Web of Science ®Google Scholar
• PITT B, ZANNAD F, REMME WJ et aL: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N EngL J. Med. (1999) 341:709–717.
   PubMed Web of Science ®Google Scholar
• PITT B, REMME W, ZANNAD F et aL: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N EngL J. Med. (2003) 348:1309–1321.
   PubMed Web of Science ®Google Scholar
• JUURLINK DN, MAMDANI MM, LEE DS et aL: Rates of hyperkalemia after publication of the Randomized Alclactone Evaluation Study. N EngL J. Med. (2004) 351:543–551.
   PubMed Web of Science ®Google Scholar
• PALMER BF: Managing hyperkalemia by inhibitors of the renin-angiotensin-aldosterone system. EngL J. Med. (2004) 351:585–592.
   PubMed Web of Science ®Google Scholar
• •Recommendations regarding the management of hyperkalaemia due to the inhibition of the renin-angiotensin-aldosterone axis in high-risk patients.
   Google Scholar
• URETSKY BF, YOUNG JB, SHAHIDI FE aL: Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. Investigative Group.. Am. Coll. CardioL (1993) 22:955–962.
   PubMed Web of Science ®Google Scholar
• PACKER M, GHEORGHIADE M, YOUNG JB et al.: Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. Engl. J. Med. (1993) 329:1–7.
   PubMed Web of Science ®Google Scholar
• [NO AUTHORS LISTED]: The effect of digoxin on mortality and morbidity in Patients with heart failure. The Digitalis Investigation Group. Engl. J. Med. (1997) 336:525–533.
   Google Scholar
• RATHORE SS, WANG Y, HM: Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl. J. Med. (2002) 347:1403–1411.
   PubMed Web of Science ®Google Scholar
• RATHORE SS, CURTIS JP, WANG Y, BRISTOW MR, KRUMHOLZ HM: Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA (2003) 289:871–878.
   PubMed Web of Science ®Google Scholar
• GUPTA S, NEYSES L: Diuretic usage in heart failure: a continuing conundrum in 2005. Eur. Heart J. (2005) 26(7):644–649.
   PubMed Web of Science ®Google Scholar
• KRAMER BK, SCHWEDA F, RIEGGER GA: Diuretic treatment and diuretic resistance in heart failure. Am. J. Med. (1999) 106:90–96.
   PubMed Web of Science ®Google Scholar
• •Detailed description of the aetiology of diuretic resistance in heart failure and recommendations concerning the optimal management of this complication.
   Google Scholar
• GRINSTEAD WC, FRANCIS MJ, MARKS GF et al.: Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am. J. CardioL (1994) 73:881–886.
   PubMed Web of Science ®Google Scholar
• COOPER HA, DRIES DL, DAVIS CE, SHEN YL, DOMANSKI MJ: Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation (1999) 100:1311–1315.
   PubMed Web of Science ®Google Scholar
• FARIS R, FLATHER M, PURCELL H et al.: Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials.. J. CardioL (2002) 82:149–158.
   Web of Science ®Google Scholar
• DRIES DL, ROSENBERG YD, WACLAWIW MA, DOMANSKI MJ: Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the of left ventricular dysfunction trials. J. Am. Coll. CardioL (1997) 29:1074–1080.
   PubMed Web of Science ®Google Scholar
• DUNKMAN WB, JOHNSON GR, CARSON PE et al.: Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 87(6 Suppl):V194–V1101.
   Web of Science ®Google Scholar
• CLELAND JG, FINDLAY I, JAFRI S et al.: The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am. Heart J. (2004) 148:157–164.
   PubMed Web of Science ®Google Scholar
• CLELAND JG, GHOSH J, FREEMANTLE N et al.: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Fail. (2004) 6:501–508.
   PubMed Web of Science ®Google Scholar
• NARANG R, CLELAND JG, ERHARDT L et al.: Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur. Heart J. (1996) 17:1390–1403.
   Google Scholar
• HALLSTROM A, PRATT CM, GREENE HL et al.: Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J. Am. Coll. CardioL (1995) 25:1250–1257.
   PubMed Web of Science ®Google Scholar
• WALDO AL, CAMM AJ, DERUYTER H et al.: Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral D-Sotalol. (1996) 348:7–12.
   Google Scholar
• [NO AUTHORS LISTED]: Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet (1997) 350:1417–1424.
   PubMed Web of Science ®Google Scholar
• SIM I, MCDONALD KM, LAVORI PW, NORBUTAS CM, HLATKY MA: Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation (1997) 96:2823–2829.
   PubMed Web of Science ®Google Scholar
• DOVAL HC, NUL DR, HO et al.: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet (1994) 344:493–498.
   Google Scholar
• SINGH SN, FLETCHER RD, SG et al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N EngL J. Med. (1995) 333:77–82.
   Google Scholar
• JULIAN DG, CAMM AJ, FRANGIN G: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet (1997) 349:667–674.
   PubMed Web of Science ®Google Scholar
• BARDY GH, LEE KL, MARK DB et al.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl. J. Med. (2005) 352:225–237.
   PubMed Web of Science ®Google Scholar
• ELKAYAM U, AMIN J, MEHRA A et aL: A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation (1990) 82:1954–1961.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN RE, BOCCUZZI SJ, CRUESS D, NATTEL S: Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation (1991) 83:52–60.
   Google Scholar
• [NO AUTHORS LISTED]: Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am. J. Cardiol. (1990) 66:779–785.
   Google Scholar
• PACKER M, O'CONNOR CM, GHALI JK et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N EngL J. Med. (1996) 335:1107–1114.
   Google Scholar
• THACKRAY S, WITTE K, CLARK AL, CLELAND JG: Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur. J. Heart Fail. (2000) 2:209–212.
   PubMed Web of Science ®Google Scholar
• COHN JN, ZIESCHE S, SMITH R et al.: Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation (1997) 96:856–863.
   Google Scholar
• ROULEAU JL, PFEFFER MA, STEWART DJ et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 356:615–620.
   PubMed Web of Science ®Google Scholar
• PACKER M, CALIFF RM, MA et al.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 106:920–926.
   PubMed Web of Science ®Google Scholar
• TEERLINK JR: Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J. Card. Fail. (2002) 8:124–127.
   PubMed Web of Science ®Google Scholar
• ANAND I, MCMURRAY J, COHN JN et al.: Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet (2004) 364:347–354.
   PubMed Web of Science ®Google Scholar
• MANN DL, MCMURRAY JJ, PACKER M et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 109:1594–1602.
   PubMed Web of Science ®Google Scholar
• CHUNG ES, PACKER M, LO KH, FASANMADE AA, WILLERSON JT: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation (2003) 107:3133–3140.
   PubMed Web of Science ®Google Scholar
• YANCY CW, SALTZBERG MT, BERKOWITZ RL et al.: Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am. J. Cardiol. (2004) 94:595–601.
   PubMed Web of Science ®Google Scholar
• NOHRIA A, LEWIS E, STEVENSON LW: Medical management of advanced heart failure. JAMA (2002) 287:628–640.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the management ofadvanced heart failure, including details regarding haemodynamic evaluation, assessment of prognosis and use of specific agents.
   Google Scholar
• PACKER M, CARVER JR, RJ et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl. J. Med. (1991) 325:1468–1475.
   PubMed Web of Science ®Google Scholar
• HAMPTON JR, VAN VELDHUISEN DJ, KLEBER FX et al.: Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet (1997) 349:971–977.
   Google Scholar
• COHN JN, GOLDSTEIN SO, BH et al.: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. Engl. J. Med. (1998) 339:1810–1816.
   Google Scholar
• SHAKAR SF, ABRAHAM WT, E et al.: Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J. Am. Coll. Cardiol. (1998) 31:1336–1340.
   PubMed Web of Science ®Google Scholar
• NANAS JN, TSAGALOU EP, KANAKAKIS J et aL: Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study. Chest (2004) 125:1198–1204.
   PubMed Web of Science ®Google Scholar
• FOLLATH F, CLELAND JG, JUST H et al.: Efficacy and safety of intravenous compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet (2002) 360:196–202.
   PubMed Web of Science ®Google Scholar
• NANAS JN, PAPAZOGLOU P, TSAGALOU EP et al.: Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am. J. Cardiol. (2005) 95:768–771.
   PubMed Web of Science ®Google Scholar
• SILVER MA, MAISEL A, YANCY CW et al.: BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest. Heart Fail. (2004) 10:1–30.
   Google Scholar
• TROUGHTON RW, FRAMPTON CM, YANDLE TG et al.: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet (2000) 355:1126–1130.
   PubMed Web of Science ®Google Scholar
• YOSHIZAWA A, YOSHIKAWA T, NAKAMURA I et al.: Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure. J. Card. Fail. (2004) 10:310–315.
   PubMed Web of Science ®Google Scholar
• PACKER M: Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation (2003) 108:2950–2953.
   PubMed Web of Science ®Google Scholar